IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Suzhou Basecare Medical IPO: Valuation Insights

Suzhou Basecare Medical IPO: Trading Debut

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Suzhou Basecare Medical / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/suzhou-basecare-medical-corporation-limited" target="_blank" data-smartkarma-citation="entities:31087:1" rel="noopener">Suzhou Basecare Medical (MED CH)</a> has developed a portfolio of genetic test kits that cover all key stages of the reproductive cycle. The initial focus of the product portfolio was on helping couples address infertility problems and increase their chances of having a healthy baby through IVF (in vitro fertilization) procedures. Basecare is pre-marketing for a Hong Kong IPO to raise $250 million, according to press reports. Basecare is backed by Hillhouse Capital and OrbiMed.</p><div class="content-highlight"><p>Basecare is an early stage of development as it sold its PGT-A kits (the core product) for limited scientific research purposes prior to NMPA approval. The commercialization of the PGT-A kits started in April 2020 after receiving NMPA approval in February 2020. As the sole NMPA-approved pre-implantation genetic testing (PGT) kit on the market, Basecare will enjoy first-mover advantages in the emerging and fast-growing PGT-A kit market. The PGT-A reagent market in China is forecasted to reach RMB6,064.9 million in 2030, according to Frost &amp; Sullivan. With a large addressable market opportunity and Basecare’s early mover advantage, we believe that Basecare’s fundamentals are attractive.</p></div>

Suzhou Basecare Medical (MED CH) has developed a portfolio of genetic test kits that cover all key stages of the reproductive cycle. The initial focus of the product portfolio was on helping couples address infertility problems and increase their chances of having a healthy baby through IVF (in vitro fertilization) procedures. Basecare is pre-marketing for a Hong Kong IPO to raise $250 million, according to press reports. Basecare is backed by Hillhouse Capital and OrbiMed.Basecare is an early stage of development as it sold its PGT-A kits (the core product) for limited scientific research purposes prior to NMPA approval. The commercialization of the PGT-A kits started in April 2020 after receiving NMPA approval in February 2020. As the sole NMPA-approved pre-implantation genetic testing (PGT) kit on the market, Basecare will enjoy first-mover advantages in the emerging and fast-growing PGT-A kit market. The PGT-A reagent market in China is forecasted to reach RMB6,064.9 million in 2030, according to Frost &amp; Sullivan. With a large addressable market opportunity and Basecare’s early mover advantage, we believe that Basecare’s fundamentals are attractive.

Suzhou Basecare Medical IPO Initiation: Improving IVF